Pembrolizumab/axitinib is approved as a first-line treatment for metastatic renal cell carcinoma (mRCC), but its safety and efficacy in later lines of therapy has not been researched. When used as a first-line treatment, the drug combination has demonstrated superior progression free survival (PFS), objective response rate (ORR), and overall survival compared with sunitinib. ...
Advertisement
Advertisement
Latest News
A study compared the gross and OOP payments for 6 different first-line mCRPC drugs during the 6 months post-treatment start.
Get recommendations for sightseeing, dining, entertainment, and more while you're in town for the conference.
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
Dr. Deek shares what “high-risk mutation” signified in his study and how patients with “high-risk mutation” should be ...
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
Dr. Deek shares how he evaluated long-term outcomes of MDT in om CSPC in both the ORIOLE and STOMP trials.
Joshua Meeks, MD, PhD, discusses ongoing research in NMIBC and the future of urothelial carcinoma care.
Researchers developed a randomized phase II clinical trial for patients with NMIBC before transurethral resection of tumors.
Advertisement
Advertisement
Editorial Advisory Board
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
Expert Interviews
Joshua Meeks, MD, PhD, discusses ongoing research in NMIBC and the future of urothelial carcinoma care.
GU Oncology Now spoke with Shyam Natarajan to discuss Avenda's iQuest and how AI can be used in the field of cancer care.
Cytoreductive nephrectomy is controversial in the metastatic RCC setting, especially in the age of immunotherapy.
Alexander Kutikov speaks about changes he pioneered in the GU surgical landscape and the future state of GU oncology care.
Colin Dinney, MD, explains the data that led to FDA approval of Adstiladrin for NMIBC and how it impacts the treatment.
Tomi Jun, MD, shares the clinical actionability and utilization of NGS for prostate cancer in a changing treatment landscape.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
Get recommendations for sightseeing, dining, entertainment, and more while you're in town for the conference.
Norman E Sharpless, MD, University of North Carolina School of Medicine, will present the keynote session.
Attendees will learn about different ways of managing renal cell carcinoma at all stages from research to practice.
Gerhardt Attard, MD, PhD, FRCP, will kick off the event with a session on advanced prostate cancer.
Video Insights
Clinical discussions with experts in the field
